GLP-1 is a category, not one product

Semaglutide and liraglutide act at the GLP-1 receptor, while tirzepatide acts at both GIP and GLP-1 receptors. Products differ in approved uses, schedules, devices, warnings and evidence.

Ask for the active ingredient and exact product rather than relying on the broad phrase GLP-1 injection.

Approved indication matters

Some medicines in this broader category are approved for chronic weight management, some for type 2 diabetes and some brands have additional labeled uses. A medicine’s popularity does not change its approved indication.

Medication selection is individualized

A prescriber may consider health history, current medicines, contraindications, prior treatment, pregnancy plans, likely benefits and possible adverse effects. The most advertised option is not automatically appropriate.

Starting treatment usually involves escalation

Many products use a lower starting dose followed by product-specific increases. This process may support tolerability and should not be accelerated to pursue faster weight loss.

Dose, schedule and missed-dose instructions must come from the exact prescription.

Treatment includes more than medication delivery

A responsible program identifies the medical practice, explains who prescribes, provides product and pharmacy information, and establishes how questions and adverse effects are handled.

Fast shipping or a simple checkout does not establish quality of care.

Approved and compounded products are different

Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. They should not be described as generic versions of approved GLP-1 medicines.

If a compounded product is proposed, ask why it is being used, which pharmacy prepares it and what exact formulation and concentration will be dispensed.

Longer-term planning begins before the first dose

Weight-management treatment may continue while it remains beneficial and tolerable under clinical supervision. Weight regain can occur after medication is stopped.

Discuss reassessment, nutrition and activity support, possible interruptions and the plan if treatment is stopped before enrolling.